MPS Loria Financial Planners LLC Acquires 412 Shares of Pfizer Inc. (NYSE:PFE)

Posted by Defense World Staff on Jun 23rd, 2023

MPS Loria Financial Planners LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 4.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,330 shares of the biopharmaceutical company’s stock after acquiring an additional 412 shares during the period. MPS Loria Financial Planners LLC’s holdings in Pfizer were worth $421,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of PFE. Moneta Group Investment Advisors LLC boosted its stake in Pfizer by 89,592.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after acquiring an additional 160,963,976 shares in the last quarter. Norges Bank bought a new position in shares of Pfizer in the fourth quarter worth approximately $3,150,472,000. Morgan Stanley lifted its stake in shares of Pfizer by 10.3% in the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after buying an additional 7,419,929 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Pfizer by 13.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 59,828,849 shares of the biopharmaceutical company’s stock worth $3,097,341,000 after buying an additional 6,972,650 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Pfizer in the first quarter worth approximately $311,238,000. Institutional investors own 67.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PFE. Barclays dropped their target price on shares of Pfizer from $43.00 to $40.00 in a research note on Wednesday, May 3rd. Bank of America dropped their target price on shares of Pfizer from $50.00 to $45.00 and set a “neutral” rating on the stock in a research note on Friday, April 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Pfizer in a research note on Wednesday, May 17th. Daiwa Capital Markets downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $38.00 target price on the stock. in a research note on Thursday, May 11th. Finally, Morgan Stanley dropped their target price on shares of Pfizer from $45.00 to $44.00 and set an “equal weight” rating on the stock in a research note on Monday, April 10th. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average target price of $47.33.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction dated Monday, May 8th. The stock was purchased at an average cost of $38.58 per share, with a total value of $38,580.00. Following the completion of the purchase, the director now directly owns 6,000 shares in the company, valued at approximately $231,480. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.05% of the company’s stock.

Pfizer Stock Down 0.4 %

Shares of PFE stock opened at $38.73 on Friday. Pfizer Inc. has a 12 month low of $36.17 and a 12 month high of $54.93. The stock has a market cap of $218.64 billion, a P/E ratio of 7.62, a P/E/G ratio of 1.33 and a beta of 0.64. The company has a current ratio of 1.37, a quick ratio of 1.11 and a debt-to-equity ratio of 0.31. The company has a 50 day simple moving average of $38.77 and a two-hundred day simple moving average of $42.81.

Pfizer (NYSE:PFE – Get Rating) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.23. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The business had revenue of $18.28 billion during the quarter, compared to analysts’ expectations of $16.49 billion. During the same period in the prior year, the company earned $1.62 earnings per share. The firm’s revenue was down 28.8% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 3.35 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th will be paid a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a dividend yield of 4.23%. Pfizer’s dividend payout ratio (DPR) is presently 32.28%.

Pfizer Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.